Literature DB >> 6374002

Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice.

P R Flatt, C J Bailey, P Kwasowski, T Page, V Marks.   

Abstract

Gastric inhibitory polypeptide (GIP), a recognized component of the enteroinsular axis, is raised in the plasma and intestine of obese hyperglycaemic (ob/ob) mice. To evaluate the control of plasma GIP and its role in the hyperinsulinaemia of the ob/ob syndrome, GIP and insulin were determined at different ages in fed mice, and at 10-12 weeks of age after fasting/refeeding and administration of GIP, different nutrients and insulin to mice fasted for 18 h. Plasma GIP and insulin were raised in adult (10- and 20-week-old) compared with younger (3- and 5-week-old) mice, although GIP was not increased in the presence of hyperinsulinaemia at 3 weeks of age. Fasting suppressed and refeeding promptly restored plasma GIP and insulin concentrations. Administration of GIP to mimic postprandial concentrations evoked a marked but transient insulin response which was protracted in the presence of rising hyperglycaemia. Orally administered fat, glucose and amino acids raised GIP concentrations with fat having a particularly strong effect. Glucose and amino acids also evoked prominent increases of insulin, but fat produced only a small rise in insulin in the absence of increasing glucose concentrations. Consistent with glucose-potentiation, a mixture of all three nutrients greatly augmented the insulin response without further increase of plasma GIP. Glucose-induced increase in endogenous insulin and doses of exogenous insulin up to 100 units/kg did not suppress basal, fat-stimulated or glucose-stimulated GIP release. The results indicate that raised GIP concentrations make an important contribution to the hyperinsulinaemia and related metabolic abnormalities of the ob/ob syndrome.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6374002     DOI: 10.1677/joe.0.1010249

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  12 in total

1.  The effect of duodenal-jejunal bypass on glucose-dependent insulinotropic polypeptide secretion in Wistar rats.

Authors:  Tammy L Kindel; Stephanie M Yoder; David A D'Alessio; Patrick Tso
Journal:  Obes Surg       Date:  2010-02-23       Impact factor: 4.129

2.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

3.  The amount and types of fatty acids acutely affect insulin, glycemic and gastrointestinal peptide responses but not satiety in metabolic syndrome subjects.

Authors:  Chee-Yan Chang; M S Kanthimathi; Alexander Tong-Boon Tan; Kalanithi Nesaretnam; Kim-Tiu Teng
Journal:  Eur J Nutr       Date:  2016-09-08       Impact factor: 5.614

4.  Increased responsiveness to glucoregulatory effect of opiates in obese-diabetic ob/ob mice.

Authors:  C J Bailey; P R Flatt
Journal:  Diabetologia       Date:  1987-01       Impact factor: 10.122

5.  Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial.

Authors:  Qibin Qi; George A Bray; Frank B Hu; Frank M Sacks; Lu Qi
Journal:  Am J Clin Nutr       Date:  2012-01-11       Impact factor: 7.045

6.  Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice.

Authors:  M H Mooney; Y H Abdel-Wahab; L M Morgan; F P O'Harte; P R Flatt
Journal:  Endocrine       Date:  2001-12       Impact factor: 3.633

7.  Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion.

Authors:  G Mingrone; G Nolfe; G Castagneto Gissey; A Iaconelli; L Leccesi; C Guidone; G Nanni; J J Holst
Journal:  Diabetologia       Date:  2009-02-20       Impact factor: 10.122

8.  Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

Authors:  V A Gault; P L McClean; R S Cassidy; N Irwin; P R Flatt
Journal:  Diabetologia       Date:  2007-06-09       Impact factor: 10.122

9.  Mouse Embryonic Fibroblasts Protect ob/ob Mice From Obesity and Metabolic Complications.

Authors:  Daniel Ferguson; Mitchell Blenden; Irina Hutson; Yingqiu Du; Charles A Harris
Journal:  Endocrinology       Date:  2018-09-01       Impact factor: 4.736

10.  Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes.

Authors:  Victor A Gault; Peter R Flatt; Clifford J Bailey; Patrick Harriott; Brett Greer; Mark H Mooney; Finbarr P M O'harte
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.